S-1: Envoy Medical Faces Nasdaq Delisting Risk Amidst Capital Raise

Envoy Medical, a hearing health company, is conducting a new offering of common stock and warrants to fund operations, while simultaneously addressing Nasdaq compliance issues and ongoing clinical trials for its Acclaim CI.

Summary

• Envoy Medical is offering an unspecified number of Class A Common Stock and Pre-Funded Warrants on a reasonable best efforts basis to raise capital.
• The company's lead product candidate, the Acclaim CI, a fully implanted cochlear implant, received Breakthrough Device Designation from the FDA in 2019.
• The pivotal clinical study for Acclaim CI received FDA approval for its second and final stage on October 3, 2025, with enrollment of the final 46 participants underway.
• Envoy Medical anticipates obtaining FDA approval for the Acclaim CI in the second half of 2027, or the first half of 2028 if a panel review is requested.
• The company reported net losses of $17.2 million for the nine months ended September 30, 2025, compared to $16.2 million for the same period in 2024.
• Accumulated deficit reached $305.7 million as of September 30, 2025, up from $284.7 million at December 31, 2024.
• Cash on hand was $3.6 million as of September 30, 2025, down from $5.5 million at December 31, 2024.
• Envoy Medical received a Nasdaq notice on November 19, 2025, for failing to meet the $1.00 minimum bid price requirement, with a compliance period until May 18, 2026.
• The company also received an exception from Nasdaq until February 23, 2026, to regain compliance with the $35 million market value of listed securities requirement.
• An Early Feasibility Study for the Acclaim CI identified a signal-to-noise issue causing a 'gurgling or sizzling background noise,' which is currently being addressed.
• The Esteem FI-AMEI, the company's first FDA-approved fully implanted hearing device (2010), failed commercially due to lack of reimbursement, but a new Congressional bill (Hearing Device Coverage Clarification Act, Feb 2024) could change its classification and potential for coverage.
• The company expects to have sufficient funds for operations through February or March 2026, assuming no additional funding from warrant exercises.

Sentiment

Score: 3

Explanation: The company is in a precarious financial position with increasing losses, declining cash, and explicit 'going concern' doubt. While there's progress in clinical trials and recent capital raises, significant product defects and Nasdaq delisting risks present substantial headwinds. The long timeline to potential FDA approval and commercialization, coupled with the need for continuous funding, indicates high uncertainty and risk.

Positives

• The Acclaim CI has received Breakthrough Device Designation from the FDA, potentially accelerating its development and review process.
• The pivotal clinical trial for the Acclaim CI has advanced to its second and final stage, with preliminary data from the first 10 participants adequately characterizing device effectiveness and no serious adverse events reported.
• The company has successfully raised capital through September 2025 and October 2025 offerings, generating gross proceeds of approximately $2.5 million and $4.0 million, respectively, with potential for additional funds from warrant exercises.
• The company's sensor technology, leveraged in both the Esteem FI-AMEI and Acclaim CI, has over two decades of experience and has proven a viable and robust alternative to external or implanted microphones.
• A new bipartisan Congressional bill, the 'Hearing Device Coverage Clarification Act,' could reclassify the Esteem FI-AMEI as a prosthetic, potentially opening up reimbursement pathways and commercial viability for the existing FDA-approved product.
• The company's patent portfolio includes 38 issued U.S. patents and 38 issued foreign patents, with expirations ranging from 2026 to 2043, providing intellectual property protection for its technologies.

Negatives

• The company has a history of significant net losses, with $17.2 million for the nine months ended September 30, 2025, and an accumulated deficit of $305.7 million.
• Cash balances decreased from $5.5 million at December 31, 2024, to $3.6 million at September 30, 2025, indicating ongoing cash burn.
• The company faces substantial doubt about its ability to continue as a going concern, requiring significant additional funding.
• Envoy Medical is not in compliance with Nasdaq's $1.00 minimum bid price requirement and has received an exception for the $35 million market value of listed securities requirement, indicating potential delisting risks.
• An Early Feasibility Study for the Acclaim CI identified a signal-to-noise issue causing 'gurgling or sizzling background noise,' which requires resolution and could delay FDA approval or commercialization.
• The commercialization of the Esteem FI-AMEI, the company's only FDA-approved product, failed due to a lack of reimbursement, highlighting challenges in market acceptance and payor coverage.
• The company expects to incur significant and increasing operating losses for the foreseeable future, particularly as it continues Acclaim CI development and prepares for commercialization.
• Existing stockholders will experience immediate and substantial dilution from the current offering and may face future dilution from additional equity offerings.

Risks

• The market price of common stock has been and may continue to be extremely volatile, potentially causing substantial losses for investors.
• There may not be enough liquidity in the Nasdaq market for the company's securities, making it difficult for securityholders to sell.
• The public float of common stock is very illiquid, and significant sales of newly registered shares could negatively impact the price.
• The company expects to need substantial additional funding, which may not be available on acceptable terms or at all, potentially requiring curtailment or discontinuation of product development.
• Clinical failure can occur at any stage of development, and current clinical experience does not guarantee future favorable results or regulatory approval for Acclaim CI.
• The company operates in a highly competitive medical device environment and may struggle to compete against larger, more diversified companies.
• Inability to successfully commercialize the Acclaim CI or a decline in demand for it could severely harm revenue generation, as the company expects to derive most revenues from this product.
• Assumptions about the addressable market for Acclaim CI may be incorrect, and the market may be smaller than estimated, or the company may fail to capture market share.
• Reliance on third parties for clinical trials, data collection, and patient enrollment introduces risks of costs and delays beyond the company's control.
• The company may become involved in securities litigation, which is expensive and could divert management attention and resources.
• Failure to meet Nasdaq's continued listing requirements could result in delisting of common stock.
• The company is highly dependent on key members of its executive management team, and their loss could impede business plans.
• The management team has limited experience managing a public company, potentially straining resources and diverting attention.
• Inability to obtain significant patent protection or adequately protect intellectual property rights could hinder market share and profitability.
• Compliance with various procedural and fee payment requirements for patent protection is crucial, and non-compliance could lead to loss of patent rights.
• The company may be subject to claims of intellectual property misappropriation or breach of non-competition agreements.
• Patent terms may not be sufficient to effectively protect products for an adequate period, especially given the long development and regulatory review times.
• Inability to enforce intellectual property rights globally due to varying foreign laws.
• Broad discretion in the use of net proceeds from offerings, which may not be used effectively.
• Purchasers in the offering will experience immediate and substantial dilution in net tangible book value per share.
• Resales of common stock by existing stockholders during the offering period could depress the market price.
• There is no established public trading market for the Pre-Funded Warrants, limiting their liquidity.
• The offering is a 'reasonable best efforts' offering with no minimum amount of securities required to be sold, meaning the company may not raise sufficient capital to pursue its business goals.
• Investors will not receive a refund if the company does not sell enough securities to fulfill its objectives due to no minimum offering amount or escrow arrangement.
• Unfavorable global economic conditions, including inflation and rising interest rates, could adversely affect business, financial condition, and ability to raise capital.
• Material weaknesses in internal control over financial reporting could lead to inaccurate financial reporting and adversely affect investor confidence.

Future Outlook

Envoy Medical anticipates obtaining FDA approval for its Acclaim CI in the second half of 2027, or the first half of 2028 if a panel review is requested. The company expects to continue incurring significant net losses for the foreseeable future, with increasing research and development, sales and marketing, and general and administrative expenses as it pursues regulatory approvals and prepares for commercialization. The commercialization strategy for Acclaim CI, if approved, will focus on a 'quality over quantity' approach, targeting approximately 30 initial surgical sites and expanding to 150 sites annually. The company also plans to pursue the CE Mark in the European Union shortly after FDA approval and explore other international markets. There is a potential for the Esteem FI-AMEI to become commercially viable if the 'Hearing Device Coverage Clarification Act' passes, leading to reimbursement policy changes.

Management Comments

• "We believe that the Acclaim CI is a first-of-its-kind cochlear implant."
• "We believe that Acclaim CI gives us the opportunity to disrupt the existing cochlear implant market."
• "Envoy Medical currently anticipates obtaining the FDAs decision on our PMA at some point within the second half of 2027 assuming that no panel review is requested. If a panel review is requested, the FDAs decision could extend to the or first half of 2028."
• "We expect to continue to incur net losses for the foreseeable future, and expect our research and development expenses, sales and marketing expenses, general and administrative expenses, and capital expenditures will continue to increase."
• "We believe that the initial results of the EFS were primarily promising."
• "We believe we have identified some of the sources of the unintended noise and strategies to mitigate that noise."
• "We believe that the fully implanted nature of the Acclaim CI will facilitate an increase in daily usage over other types of cochlear implants because the device can be used 24-hours a day."
• "We believe we can increase penetration rates for adult cochlear implants in the U.S."
• "We believe strong relationships can be built with both surgical teams and audiologists to ensure both are able to understand the options and benefits of the technology and differentiate themselves from the marketplace by offering and working with the Acclaim CI."
• "We believe that this categorization [of Esteem FI-AMEI as a hearing aid] is inaccurate as, unlike a hearing aid which is essentially an externally worn microphone and speaker simply making sounds louder, the Esteem FI-AMEI is fully implanted and replaces the function of the middle ear."
• "The Company believes that the lawsuit is meritless and has been defending this matter vigorously."
• "Management believes that its existing cash balances combined with future capital raises through debt and equity and cash receipts from product sales will be sufficient to fund ongoing operations through at least one year from the date the unaudited condensed consolidated financial statements are issued."

Industry Context

Envoy Medical operates in the hearing health industry, focusing on innovative medical technologies. Its lead product, the Acclaim CI, aims to disrupt the cochlear implant market, which is currently dominated by a few major manufacturers (Cochlear Ltd., Advanced Bionics (Sonova), Med-El). The industry trend is towards improved usability, connectivity, lifestyle integration, and miniaturization of devices, which aligns with Acclaim CI's fully implanted design. There's also a trend of loosening clinical candidacy requirements for cochlear implants, expanding the addressable market. The company's previous product, Esteem FI-AMEI, highlights the critical role of reimbursement pathways in the medical device industry, as its commercial failure was primarily due to classification as a hearing aid rather than a prosthetic. The potential passage of the 'Hearing Device Coverage Clarification Act' could significantly alter the market for fully implanted active middle ear implants.

Comparison to Industry Standards

• Envoy Medical's Acclaim CI, as a fully implanted cochlear implant, aims to differentiate itself from traditional partially implanted devices offered by industry leaders like Cochlear Ltd., Advanced Bionics (Sonova), and Med-El by offering 24-hour use, hearing in water, and reduced stigma.
• The current market penetration rate for cochlear implants in the adult population is estimated at 5-8%, leaving a significant untapped market of approximately 2.8 million adults in the U.S. who could qualify, which Envoy Medical aims to capture.
• The assumed selling price for a traditional cochlear implant in the U.S. is $30,000, and Envoy Medical believes the Acclaim CI could command a higher average selling price due to its unique advantages.
• Unlike the Esteem FI-AMEI, which was classified as a hearing aid and lacked Medicare/Medicaid coverage, the Acclaim CI is expected to be eligible for established cochlear implant reimbursement pathways, aligning with industry standards for successful commercialization.
• Envoy Medical's competitors, such as Cochlear Ltd. (with approximately 60% global market share and $18 billion market capitalization), have substantially greater sales, financial resources, and established distribution networks, posing a significant competitive challenge for Envoy Medical's market entry.
• The company's go-to-market strategy of carefully selecting 30 initial surgical sites and gradually expanding contrasts with the broader distribution networks of established competitors, reflecting a focus on quality and controlled growth for a novel device.

Management Changes

Corporate Governance

Legal Proceedings

• A lawsuit was filed on November 14, 2023, by Atlas Merchant Capital SPAC Fund I LP against the company, former CEO Whitney Haring-Smith, former CFO Daniel Hirsch, and Anzu SPAC GP I LLC in the Delaware Court of Chancery.
• Atlas alleges that it was improperly prevented from redeeming its shares of Common Stock and seeks approximately $9.4 million in damages, plus interest and legal fees.
• The company asserts that Atlas did not comply with redemption requirements and believes the lawsuit is meritless, defending it vigorously.
• On March 3, 2025, the court partially granted a motion to dismiss, narrowing the scope of the litigation.
• The company has standard indemnification obligations to its former CEO and CFO for this lawsuit.
• As of September 30, 2025, no accruals for potential losses related to this or other litigation claims have been recorded, as management determined no potential loss is probable and reasonably estimable.

Related Party Transactions

• The company received $30 million in term loan financings from GAT Funding, LLC (GAT), an entity controlled by Glen A. Taylor (a former director and controlling stockholder), between February 2024 and June 2025.
• On August 25, 2025, GAT forgave all outstanding principal and accrued interest on these Term Loans in exchange for a $100,000 payment from the company.
• On September 4, 2025, the company entered into a Voting and Warrant Extension Agreement with Glen Taylor and affiliated entities, extending the expiration date of Term Loan Warrants to December 31, 2028, in exchange for voting agreements.
• The company leases its headquarters office space in Minnesota from Taylor Corporation, an entity controlled by Glen Taylor, with lease payments of $220,000 in 2024.
• The company has a shared services arrangement with Taylor Technology Services, Inc., also indirectly owned by Glen Taylor, for support services, incurring less than $100,000 in expenses for the nine months ended September 30, 2025, and 2024.
• The company entered into a consulting agreement with Robert Potashnick (Interim CFO) through his wholly-owned entity, Oasis Business Consulting, LLC, recognizing $95,000 in expense for the nine months ended September 30, 2025.

Stakeholder Impact

• **Shareholders:** Face significant dilution from current and future equity offerings, and potential losses due to stock price volatility and Nasdaq delisting risks. The 'going concern' doubt poses a fundamental risk to investment value. The lawsuit by Atlas Merchant Capital could result in substantial costs and further impact shareholder value.
• **Employees:** The company's ability to attract and retain skilled personnel is crucial for R&D and commercialization. Increased operating expenses, including employee compensation, are expected. Management changes, such as the Interim CFO appointment, may affect internal dynamics.
• **Customers (Patients):** The Acclaim CI aims to provide improved hearing solutions, but the identified signal-to-noise issue and potential delays in FDA approval could impact patient access and satisfaction. Existing Esteem FI-AMEI patients will continue to be supported, but new implantations are limited without reimbursement changes.
• **Suppliers:** The company's reliance on single-source suppliers for critical components makes it vulnerable to supply shortages, increased costs, and quality issues, which could affect product development and commercialization timelines.
• **Creditors:** The forgiveness of $30 million in related-party debt by GAT Funding, LLC, significantly reduced the company's debt burden, but the ongoing need for substantial additional funding and 'going concern' doubt still present risks for future creditors.
• **Regulatory Authorities (FDA, Nasdaq):** The company is actively engaged with the FDA for Acclaim CI approval and with Nasdaq to maintain its listing, indicating compliance efforts are a significant operational focus and potential source of risk.

Next Steps

• Continue enrollment of the final 46 study participants for the second stage of the Acclaim CI pivotal clinical trial.
• Collect and analyze data from all 56 patients after their 12-month visits for the Acclaim CI pivotal clinical study.
• Submit a Premarket Approval (PMA) application to the FDA for the Acclaim CI upon finalization of clinical study results.
• Address and resolve the identified signal-to-noise issue in the Acclaim CI design.
• Actively monitor the market value of listed Common Stock and consider options to regain compliance with Nasdaq's $35 million MVLS requirement by February 23, 2026.
• Regain compliance with Nasdaq's $1.00 minimum bid price requirement by May 18, 2026, potentially through a reverse stock split if necessary.
• Seek additional funding through equity offerings, debt financings, or other capital sources to support ongoing operations beyond February/March 2026.
• Pursue the Conformit Europenne mark (CE Mark) in the European Union shortly after FDA approval for Acclaim CI.
• Address commercial activities outside of the United States, including Australia, Brazil, and parts of Asia, once FDA approval is more advanced.
• Invest in patient advertising, provider education and training, distribution capabilities, and physician strategic relationships post-FDA approval for Acclaim CI.
• Continue efforts to pursue positive reimbursement changes for fully implanted active middle ear implants, potentially benefiting the Esteem FI-AMEI.

Key Dates

Recommendation

Envoy Medical presents a high-risk investment profile. The company has a history of significant and increasing net losses, a substantial accumulated deficit, and critically, an explicit 'going concern' doubt, indicating severe financial instability. Cash reserves are dwindling, and while recent capital raises provide some liquidity, they also contribute to significant shareholder dilution. The stock is currently trading below Nasdaq's minimum bid price, and the company faces potential delisting, which would further impair liquidity and investor confidence. Operationally, while the Acclaim CI has FDA Breakthrough Device Designation and is in pivotal trials, a critical signal-to-noise defect has been identified, which could lead to material delays in FDA approval and commercialization. The long timeline to potential profitability (H2 2027 or H1 2028 at best) and the highly competitive market, coupled with the need for continuous, uncertain future funding, make the stock a 'strong sell' for risk-averse investors. Even for speculative investors, the fundamental financial distress and product development challenges outweigh the potential upside at this stage.

Keywords

Envoy Medical, Acclaim CI, Cochlear Implant, FDA Approval, Medical Device, Hearing Loss, Clinical Trial, Nasdaq Listing, Capital Raise, Warrants, Biotechnology, Healthcare Technology, Sensorineural Hearing Loss, Esteem FI-AMEI, Intellectual Property